All News
JAK inhibitors in GCA?
The SELECT-GCA study, looking at upadacitinib in GCA, anchored the ACR 2024 opening plenary for a reason - it is highly notable and badly needed.
Read Article
ACR 2024 - Day 1 Report
ACR Convergence 2024 opened today with a full slate of presentations, posters and specialty meetings. The meeting began with a flip: the plenary sessions started at 9AM and the poster session began at 1030 AM. Below are some of the highlights from day one in Washington, DC.
Read Article
axSpA: Moving the needle in time to diagnosis
The journey to axial spondyloarthritis (axSpA) diagnosis is often prolonged and challenging. Understanding the factors contributing to the delays is important to improve the clinical, psychological, social and economic outcomes. Data from the SPACE cohort (abstract 0566), the ASAS-PerSpA study (abstract 0550) and the US Claims data (abstract 0558), allows us to highlight the barriers to early diagnosis of axSpA and identify opportunities for improving early diagnosis and treatment.
Read Article
A study presents a novel urinary biomarker panel that predicts histologically active lupus nephritis (LN) with high accuracy.
Key findings:
- AUC of 90% for predicting NIH Activity Index > 2, outperforming traditional biomarkers.
- Identified 12 critical proteins linked to… https://t.co/6ZhqNaxpQM
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
The DESIR cohort of Dr. Franc et al. showed that female pts with early axSpA had significantly lower AMH levels vs. general population reflecting low ovarian reserve & fertility.
Mechanism?
Bigger studies need to be done
@RheumNow #ACR24 abs577 https://t.co/842rX79bq6
sheila RHEUMarampa ( View Tweet)
@KDAO2011 help me out here; what is the point of analyses like this?
NO difference in PROs comparing voclo vs plbo...
...but if you split by responder status its different
Prescribing the drug doesn't help PROs, but when it works it works? 🤔
#ACR @RheumNow Abstr#1538 https://t.co/339drHwUuK
Mike Putman EBRheum ( View Tweet)
The @ACRheum RA outcome measures toolkit has all the relevant tools for measuring outcomes in rheumatoid arthritis (and exactly how to do it).
https://t.co/GZ7tZ6fNMK
Great for all US rheumatologists, but also very handy for all of us globally
#ACR24 16S30 @JYazdany @RheumNow https://t.co/MSHA353MKR
Links:
David Liew drdavidliew ( View Tweet)
Abstract 333 showed that in a cohort of patients with IIM-ILD increased age, PH, FVC decline at 1 yr, SOB at 2 years were predictors for mortality and lung transplant ! #ACR24 @RheumNow https://t.co/NgOj7WKeE3
Gabriela Martinez Zayas, MD MartinezZayasMd ( View Tweet)
Factors associated w/ secukinumab response in PsA?
Analysis of 2.7k pt in EuroSpA
Associated w/ favorable response
❗️elevated CRP >10 mg/L
❗️fewer prev tx
Associated w/ lower response:
❗️smoking
❗️higher patient global score / HAQ
@RheumNow #ACR24 Abstr 2325
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
Systematic review & meta-analysis by DrHChaudhary et al @DaoudAnsaam @mmagrey1
showed that males w/ axSpA who were treated with biologics had ⬆️ BASDAI150 response & likely w/ ASDAS low dse activity vs. females w/axSpA
Again, effect of gender differences
@RheumNow #ACR24 abs599 https://t.co/2DPYC8exES
sheila RHEUMarampa ( View Tweet)
What is my risk of developing SLE?
Abstract 0843 highlights a predictive model that accurately classifies SLE risk using genetics, lifestyle, and environmental factors. Model 3 (genetics + environment + lifestyle) performed the best compared to models 1 and 2.
@RheumNow #ACR24 https://t.co/sk9oG0OY3W
Akhil Sood MD AkhilSoodMD ( View Tweet)
Race of b/tsDMARDs in RA, the “JAK-pot” study.
JAKi and TNFi with more rapid early improvement in CDIA, HAQ, and pain compared to ABA or IL-6 inhibitors…..although effects blunted after adjusting for patient and RA characteristics
#ACR24 @RheumNow ABST#0501 https://t.co/8M4wX3LAbW
Jiha Lee JihaRheum ( View Tweet)
How early is early?
Data from SPACE cohort included 548 pts with CBP (<2y duration) and different SpA features followed over 2years.
-At the end of 2 years, 39% pts were dx with axSpA.
-Median time to dx: 35 months.
-HLAB27+, sacroilitis on MR and peripheral arthritis were the… https://t.co/AYtJCp8yno https://t.co/VL7KSrpvp9
Links:
Adela Castro AdelaCastro222 ( View Tweet)
Cross-sectional study finds metabolic dysregulation in RA-ILD is indicative of poor prognosis- FGF-21 assoc w. poor survival.
Another link btwn CV risk factors, metabolic syndrome & RA? Should we be doing more to manage metabolic risk factors in RA-ILD?
Ab0803 #ACR24 @RheumNow
Mrinalini Dey DrMiniDey ( View Tweet)
Medication-assisted weight loss has boomed in recent yrs. How does weight loss affect disease activity & PROs in RMDs?
≥5% weight loss, after taking a med, led to better disease activity & QoL
Data may inform RCTs to explore effect of these meds in RMDs
Ab0845 #ACR24 @RheumNow
Mrinalini Dey DrMiniDey ( View Tweet)
Don’t miss the “window of opportunity” for aggressive treatment in early RA!
with active RA, risk of ILD 6x and RA-related lung disease 4x higher
#ACR24 @RheumNow ABST#0802 https://t.co/yxlfInte6A
Jiha Lee JihaRheum ( View Tweet)
Harkins @DrTrishHarkins et al. 1 year outcomes of 65 PMR patients treated in FTC. 32.7% experienced relapse, 28% still on GCs, 21% on tocilizumab. @RheumNow #ACR24 Abstr#0739 https://t.co/uYBYhPqGQE https://t.co/n9x9BDTPKg
Links:
Richard Conway RichardPAConway ( View Tweet)
#Disparites posters #ACR24 - Analyzed 954 SLE patients
- Black and Asian patients had higher severe damage events
- Neighborhood disadvantage (ADI) linked to increased severe damage
- Older age and comorbidities increased damage risk
abst#0362 @rhuemnow
Bella Mehta bella_mehta ( View Tweet)
Disparities posters #ACR24
- Analyzed 10,604 SLE patients
- 18.7% in the lowest SES group experienced functional status decline vs. 12.5% in the highest SES group
- African American patients and Greater neighborhood deprivation did worse
#ACR24 abst#0190
@RheumNow
Bella Mehta bella_mehta ( View Tweet)
More steroid-sparing options for #IgG4RD!
Abstract 0775: In pts w/ IgG4:
- Inebilizumab (CD19-monoclonal ab) vs placebo associated with reduced risk of flare (HR 0.13; 95% CI 0.06, 0.28)
AEs: infections, infusion reactions, lymphopenia
#ACR24 @RheumNow https://t.co/Vr5hcd2E7E
Akhil Sood MD AkhilSoodMD ( View Tweet)
